Cybin Shares Rise After Positive Phase 2a Readout for Short-Acting Depression Therapy
Cybin Inc (NYSE: HELP) shares gained 8.2% following publication of Phase 2a results showing a single 21.5 mg dose of SPL026 produced a clinically significant reduction in depressive symptoms versus placebo at two weeks, with effects emerging within one week and persisting for months in some participants. The randomized, placebo-controlled study met…